Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Tips for Designing Studies That Actually Reveal Causal Inference

Ruth Jessen Hickman, MD  |  Issue: May 2021  |  May 13, 2021

kentoh / shutterstock.com

kentoh / shutterstock.com

Dr. Kim also emphasized the importance of clearly defining treatment exposures, so the two comparator groups can be presumed to be identical with respect to their risk of outcomes. This can be trickier than it seems at first. For example, it’s important to consider the concept of positivity, which states that the possibility of receiving a treatment must be greater than zero (this would not be true, for example, in case of a drug contraindication). The interventions themselves must also be well defined in areas of timeline, inclusion and exclusion criteria, and other factors.

For people intimidated by some of the details of advanced technical methods in causal inference, Dr. Kim pointed out that not all questions require such methods be employed. “Try to make the study question very simple first,” she advised. “Once you have a very straightforward causal question, start with a simpler method, and you will build up your confidence in applying advanced methods later,” she said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

For those looking to learn more about causal inference, Dr. Kim strongly recommends a free textbook by Miguel A. Hernán, MD, MPH, ScM, DrPH, and James M. Robins, MD, Causal Inference: What If, as a good entry point into the topic.1 These researchers were the first to explicitly propose a “target trial” approach to organizing an observational study, an approach also recommended by Dr. Kim.2

Target Trials

In the second part of the March 4 session, Daniel H. Solomon, MD, MPH, chief of the Section of Clinical Sciences at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, expanded on Dr. Kim’s recommendation to follow a target trial approach when designing rigorous observational studies. Dr. Solomon also serves as principal investigator on the VERITY grant and as editor in chief of Arthritis & Rheumatology.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Solomon noted that accepted research methodologies can evolve over time. For example, the Bradford Hill causal criteria have fallen out of favor somewhat as the research community has realized their limitations. In contrast, the target trial approach has been gaining momentum in recent years.

“For each observational analysis for causal inference, we can imagine a hypothetical randomized trial that we would likely prefer to conduct. That is the target trial,” says Dr. Solomon.

He noted that clinicians want their decision making to be informed by causal knowledge about comparative effectiveness and comparative safety. Deferring decisions is not really an option because it just maintains the status quo.

“A relevant randomized trial would, in principle, answer each causal question about comparative effectiveness and safety,” he said. “But we often can’t have randomized trials because they are expensive. They are sometimes unethical, depending on the study. They can be impractical, and they often can’t deliver timely answers.”

Although observational analyses cannot provide the highest level of evidence, the target trial approach provides a way to carefully and thoughtfully design observational studies, so they can provide more accurate information to inform clinical practice.

The idea is to explicitly emulate the envisioned randomized trial with observational data. This requires rigorous analysis and thorough description of various categories as they would occur in a randomized trial: eligibility criteria, treatment strategies, assignment criteria, assignment procedures, follow-up period, outcome, causal contrast of interest and analysis plan. Problems in any of these areas can lead to results that are difficult to interpret and that cannot help guide wise clinical decisions.

For example, Dr. Solomon described a systematic review he helped perform that analyzed the comparative effectiveness of different rheumatoid arthritis strategies through the lens of a target trial emulation framework.3 Such work might be very insightful, as randomized, controlled trials have been slow to fill this hole in the literature. But 29 out of the 31 trials included in their analysis had one or more design flaws, as determined by a target trial emulation approach, limiting their applicability.

Dr. Solomon sees target trial emulation as a way to strengthen causal inference and thus the strength of our confidence in found associations. “Unfortunately, with observational data, people are often a bit sloppy. That results in a lot of vagaries in the literature. We think that target trial emulation is a way of creating some rigor around how one does these comparative effectiveness studies to bring us closer to causation.”

The March 11 sessions further explored mediation analysis, a highly pertinent concept for interpreting and designing both observational and randomized trials.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:Research Rheum Tagged with:Causestudy designtrials

Related Articles

    Thick Skin & Solid Research: Necessary Ingredients for Publishing Success

    June 1, 2023

    Scientific publishing requires a commitment to clear writing, concise narratives and a willingness to accept feedback. Daniel Solomon, MD, editor-in-chief of Arthritis & Rheumatology, provides insights into his experiences.

    Research Roundup: Abstract Data Presented at ACR Convergence 2021

    February 11, 2022

    The research presented at ACR Convergence 2021 had a broad scope. Below are details on three studies that addressed cardiovascular safety in treat-to-target strategies, phase 2 study results on the efficacy of tigulixostat and the impact of patient preference on treatment adherence. Take our quiz after you read this article. Treat to Target Abstract L06:…

    Meet the Incoming Arthritis & Rheumatology Editor in Chief, Dr. Daniel Solomon

    December 18, 2019

    Daniel Solomon, MD, MPH, has practiced rheumatology for more than 20 years, all while conducting translational and clinical research and teaching young clinicians. Soon, he will also step into the role of editor in chief of Arthritis & Rheumatology, as Richard J. Bucala, MD, PhD, ends his tenure. He will assume some duties during a…

    The 2020 ACR Awards of Distinction & Masters Class

    November 12, 2020

    Presidential Gold Medal The highest award the ACR can bestow, the Presidential Gold Medal is awarded in recognition of outstanding achievements in rheumatology over an entire career. This year’s award went to James O’Dell, MD, the Stokes-Shackleford Professor of Internal Medicine, vice chair of internal medicine and chief of the Division of Rheumatology at the…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences